XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Significant Accounting Policies, Research and Development Expenses (Details) - Novartis [Member] - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2017
Research and Development Expenses [Abstract]    
Sublicense fee expenses $ 48.4  
Non-cash sublicense expenses 33.4  
Allocable arrangement consideration 108.4  
Portion of upfront payment paid as sublicense fee to Ionis $ 15.0  
Percentage of license fees, milestone payments and royalties paid as sublicense fee to Ionis   50.00%